Background: Finite resources are available to fund research, and it is important to ensure stakeholder input is identified and prioritized. In this light, the KCRNC and CIHR sponsored a consensus-based priority-setting partnership that brought together a group of patients, caregivers, and clinicians to identify the top 10 research priorities in kidney cancer (Table), with a consensus document published in 2017. The final step of the prioritization process was to determine how research funding allocation has aligned with these previously identified priority areas. We report the results of this assessment. Methods: We queried publicly available Canadian and American research databases to identify all research funds allocated to kidney cancer from 2018-2020. Each funded project was assessed to determine which priority areas were addressed. We evaluated the percent of projects and percent of funding dollars (converted to USD) allocated to priority areas. Projects were stratified by country, type of research (basic science/translational or clinical), and cancer stage of focus (localized and/or metastatic). Results: A total of 121 kidney cancer research projects were funded between 2018-2020, with 15 Canadian projects (total $ = 1,906,398 USD) and 106 American projects (total $ = 56,317,386 USD). Most projects were basic science or translational (88%). Half (50%) of the projects focused on localized cancer while 26% of projects focused on metastatic kidney cancer. Overall, 49% of projects aligned to one priority area, 47% of projects aligned to multiple priority areas, and 4% of projects were not aligned to priority areas. The priority areas which received the most funding were causes of kidney cancer (priority #10, 64% of funds), biomarkers (priorities #1b+1c+5, 59%), and immunotherapies (priority #4, 41%)(Table). Unfunded priority areas were supportive care (priority #6) and the role of biopsy in kidney cancer management (priority #8). Conclusions: Nearly all kidney cancer projects funded since 2018 were aligned with one or multiple stakeholder-identified research priority areas, although some priority areas remain underfunded. Mechanisms to improve distribution of funding to all priority areas may be warranted.